Marshall Wace, LLP Hutchmed (China) LTD Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
A detailed history of Marshall Wace, LLP transactions in Hutchmed (China) LTD stock. As of the latest transaction made, Marshall Wace, LLP holds 18,102 shares of HCM stock, worth $291,623. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,102Holding current value
$291,623% of portfolio
0.0%Shares
9 transactions
Others Institutions Holding HCM
# of Institutions
70Shares Held
6.77MCall Options Held
8.2KPut Options Held
9.2K-
Schroder Investment Management Group London, X02.77MShares$44.6 Million0.04% of portfolio
-
Allianz Asset Management Gmb H Munich, 2M1.12MShares$18.1 Million0.02% of portfolio
-
Ubs Group Ag378KShares$6.09 Million0.0% of portfolio
-
State Street Corp Boston, MA348KShares$5.6 Million0.0% of portfolio
-
Aia Group LTD Hong Kong, K3315KShares$5.08 Million0.12% of portfolio
About HUTCHMED (China) Ltd
- Ticker HCM
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 172,955,008
- Market Cap $2.79B
- Description
- HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...